'''RU-28306''' is a tricyclic [[tryptamine]] derivative which acts as a [[serotonin receptor]] agonist, with selectivity for [[5-HT1 receptor|5-HT<sub>1</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub>]] subtypes. It can be regarded either as a conformationally constrained derivative of [[Dimethyltryptamine|DMT]], or a structurally simplified analogue of [[LSD]], but the [[binding affinity]] of [[racemic]] RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT<sub>2</sub> subtypes and lower for 5-HT<sub>1</sub>.<ref name="pmid3657392">{{cite journal | vauthors = Taylor EW, Nikam S, Weck B, Martin A, Nelson D | title = Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites | journal = Life Sciences | volume = 41 | issue = 16 | pages = 1961–9 | date = October 1987 | pmid = 3657392 | doi = 10.1016/0024-3205(87)90749-1 }}</ref> It has been sold as a [[designer drug]] and was first reported to the [[EMCDDA]] by a forensic laboratory in Slovenia in 2017.<ref>[http://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA]</ref>
'''RU-28306''' is a synthetic [[indole alkaloid]] derivative which acts as a [[serotonin receptor]] agonist, with selectivity for [[5-HT1 receptor|5-HT<sub>1</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub>]] subtypes. It can be regarded either as a tricyclic derivative of [[Dimethyltryptamine|DMT]], or a structurally simplified analogue of [[LSD]], but the [[binding affinity]] of [[racemic]] RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT<sub>2</sub> subtypes and lower for 5-HT<sub>1</sub>.<ref name="pmid3657392">{{cite journal | vauthors = Taylor EW, Nikam S, Weck B, Martin A, Nelson D | title = Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites | journal = Life Sciences | volume = 41 | issue = 16 | pages = 1961–9 | date = October 1987 | pmid = 3657392 | doi = 10.1016/0024-3205(87)90749-1 }}</ref> It has been sold as a [[designer drug]] and was first reported to the [[EMCDDA]] by a forensic laboratory in Slovenia in 2017.<ref>[http://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA]</ref>
RU-28306 is a synthetic indole alkaloid derivative which acts as a serotonin receptor agonist, with selectivity for 5-HT1 and 5-HT2 subtypes. It can be regarded either as a tricyclic derivative of DMT, or a structurally simplified analogue of LSD, but the binding affinity of racemic RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT2 subtypes and lower for 5-HT1.[1] It has been sold as a designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017.[2]
^Taylor EW, Nikam S, Weck B, Martin A, Nelson D (October 1987). "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences. 41 (16): 1961–9. doi:10.1016/0024-3205(87)90749-1. PMID3657392.